Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MOMA-313 Monotherapy or in Combination With Olaparib in Advanced Solid Tumors
NCT06545942Phase 1Recruiting
- Sponsor
- MOMA Therapeutics
- Start
- Aug 2024
- Primary completion
- May 2027
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label trial of moma-313 in solid tumor, prostate cancer (PCa), pancreatic cancer (PC) and 2 more (2 arms), sponsored by MOMA Therapeutics. Primary endpoint: Number of participants with Adverse Events, Dose-Limiting Toxicities, Serious Adverse Events, and/or Adverse Events leading to discontinuation up to 35 months. Started Aug 2024; status: recruiting.
02
Drugs
moma-313
03
Conditions
solid tumorprostate cancer (PCa)pancreatic cancer (PC)breast cancerovarian cancer
Beyond the preview
Go deeper on NCT06545942.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06545942.